































via	 a	 one‐pot	 reaction	 of	 3‐acetyl‐2,5‐diclorothiophene	 (1),	 aryl	 aldehydes	 (2a‐i)	 and
thiourea	 in	methanolic	 solution	of	potassium	hydroxide	under	 reflux	 conditions.	All	 newly
synthesized	 compounds	were	 characterized	 by	 extensive	 NMR	 analysis,	 including	 1D	NMR
experiments	(1H	and	13C)	and	2D	NMR	experiments	(COSY,	HMBC	and	HSQC),	as	well	as	ESI‐
MS	and	HRESI‐MS	data.	The	antimicrobial	activity	of	all	new	compounds	 (3a‐f)	was	 tested















[1‐4],	 antidepressant	 [5],	 antitubercular	 [6],	 antihistamines	
[7],	 anti‐HIV	 [8],	 and	 others	 [9‐12].	 Pyrimidine	 rings,	 on	 the	
other	 hand,	 are	 important	 substructures	 in	 natural	 products	
like	 nucleic	 acids	 and	 vitamin	 B1	 [13,14].	 Different	 pyrimi‐
dines	 have	 shown	 a	 pharmaceutical	 importance	 because	 of	
their	 biological	 activity	 such	 as	 antifungal	 [15],	 antiviral	 [16‐
18],	 anti‐inflammatory	 [19],	 antileishmanial	 [20]	 and	 anti‐
cancer	[20,21].	
In	 the	 view	 of	 these	 facts,	 we	 report	 the	 synthesis,	
characterization,	 and	 antimicrobial	 activity	 of	 new	 diaryl‐







Thiourea	 was	 purchased	 from	 Aldrich.	 3‐Acetyl‐2,5‐







spectrometers	 (300‐600	MHz).	Chemical	 shifts	δ	 are	given	 in	
parts	per	million	(ppm)	and	were	determined	from	the	center	
of	 the	 respective	 coupling	 pattern	 (s:	 singlet,	 d:	 doublet,	 dd:	
doublet	of	doublet,	t:	triplet).	The	solvent	signals	were	used	as	
internal	 standard	 (DMSO‐d6:	 δ	 (1H)	 2.50	 ppm,	 δ	 (13C)	 39.52	
ppm).	ESI‐HMRS	measurements	were	performed	on	a	LTQ‐FT	
mass	spectrometer	(Thermo	Fisher	Scientific).		
Thin	 layer	 chromatography	 (TLC)	 monitoring	 of	 the	
reaction	 was	 carried	 out	 using	 analytical	 TLC	 plates	 coated	
with	 silica	 gel	 (60F254,	 Merck).	 Preparative	 column	 chroma‐



















was	 cooled,	 poured	 into	 ice	 water	 (150	 mL),	 and	 then	
neutralized	 with	 hydrochloric	 acid.	 The	 obtained	 solid	 was	






J	 =	8.4,	 1.6	Hz,	1H,	H‐4"),	7.40	 (dd,	 J	 =	9.3,	 1.6	Hz,	1H,	H‐6"),	
7.49	(t,	J	=	7.7	Hz,	1H,	H‐5"),	7.61	(d,	J	=	8.4	Hz,	1H,	H‐3"),	9.01	
(bs,	1H,	NH‐3),	9.95	(bs,	1H,	NH‐1).	13C	NMR	(150	MHz,	DMSO‐
d6,	 δ,	 ppm):	 175.5	 (CS‐2),	 142.1	 (Cq‐1"),	 132.8	 (CH‐3"),	 131.4	
(Cq‐6),	 129.5	 (CH‐4"),	 128.5	 (CH‐5"),	 128.3	 (CH‐6"),	 127.4	
(CH‐4'),	127.3	(Cq‐3'),	124.9	(Cq‐5'),	123.7	(Cq‐2'),	120.0	(Cq‐
2"),	 102.4	 (CH‐5),	 54.6	 (CH‐4).	 MS	 (+ESI,	 m/z	 (%)):	 443	
([M+Na+2]+,	 30),	 863	 ([2M+Na]+,	 13),	 1283	 ([3M+Na]+,	 26).	
HRMS	 (+ESI,	m/z):	 440.8657	 [M+Na]+,	 442.8629	 [M+Na+2]+,	






(m,	 2H,	 H‐5",6"),	 7.53	 (m,	 2H,	 H‐2",4"),	 9.13	 (bs,	 1H,	 NH‐3),	
9.93	 (bs,	 1H,	 NH‐1).	 13C	 NMR	 (150	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
175.2	(CS‐2),	146.6	(Cq‐1"),	132.3	(Cq‐6),	131.5	(CH‐5"),	131.0	
(CH‐2"),	 129.8	 (CH‐4"),	 128.3	 (CH‐4'),	 127.9	 (Cq‐3'),	 126.1	
(CH‐6"),	125.4	(Cq‐5'),	124.4	(Cq‐2'),	122.4	(Cq‐3''),	104.5	(CH‐
5),	 54.4	 (CH‐4).	 MS	 (‐ESI,	m/z	 (%)):	 419	 ([M‐H]‐,	 100),	 421	
([M‐H+2]‐,	49),	423	([M‐H+4]‐,	9).	HRMS	(‐ESI,	m/z):	418.8663	







9.10	 (bs,	1H,	NH‐3),	9.88	 (bs,	1H,	NH‐1).	 13C	NMR	 (150	MHz,	
DMSO‐d6,	 δ,	ppm):	175.0	 (CS‐2),	162.9,	161.3	 (d,	 JCF	=	251.20	
Hz,	 Cq‐4"),	 140.3	 (Cq‐1"),	 132.3	 (Cq‐6),	 129.2,	 129.1	 (d,	 JCF	 =	
8.61	Hz,	CH‐2",6"),	128.3	(CH‐4’),	127.7	(Cq‐3'),	125.3	(Cq‐5'),	
124.3	(Cq‐2'),	116.0,	115.8	(d,	JCF	=	21.65	Hz,	CH‐3",5"),	104.9	
(CH‐5),	 54.3	 (CH‐4).	 HRMS	 (+ESI,	 m/z):	 380.9461	 [M+Na]+,	
382.9433	 [M+Na+2]+,	 384.2077	 [M+Na+4]+,	 (calcd.	 for	
C14H9Cl2FN2S2Na,	380.9460).	
4‐(3‐Bromo‐4‐methoxyphenyl)‐6‐(2,	5‐dichlorothiophen‐3‐





9.08	 (bs,	1H,	NH‐3),	9.48	 (bs,	1H,	NH‐1).	 13C	NMR	 (125	MHz,	
DMSO‐d6,	 δ,	 ppm):	175.0	 (CS‐2),	 155.5	 (Cq‐4"),	137.7	 (Cq‐1"),	
132.4	 (Cq‐6),	 131.7	 (CH‐2"),	 127.8	 (CH‐4'),	 127.8	 (CH‐6"),	
127.6	 (Cq‐3'),	 125.4	 (Cq‐5'),	 124.3	 (Cq‐2'),	 113.5	 (CH‐5"),	
110.9	 (Cq‐3"),	 104.7	 (CH‐5),	 56.8	 (4"‐OCH3),	 53.9	 (CH‐4).	MS	
(+ESI,	m/z	(%)):	451	([M+H]+,	100),	453	([M+H+2]+,	49),	455	
([M+H+4]+,	9).	HRMS	(+ESI,	m/z):	450.8922	[M+H]+	,	452.8889	








8.73	 (bs,	1H,	NH‐3),	9.75	 (bs,	1H,	NH‐1).	 13C	NMR	 (125	MHz,	
DMSO‐d6,	 δ,	 ppm):	175.7	 (CS‐2),	 160.6	 (Cq‐4"),	157.0	 (Cq‐2"),	
132.4	 (Cq‐6),	 128.2	 (CH‐4'),	 128.1	 (CH‐6"),	 127.3	 (Cq‐3'),	
125.3	 (Cq‐5'),	 124.2	 (Cq‐1"),	 123.91	 (Cq‐2'),	 105.4	 (CH‐5"),	
104.7	 (CH‐5),	 99.0	 (CH‐3"),	 56.1	 (OCH3‐2"),	 55.8	 (OCH3‐4")	
49.8	(CH‐4).	HRMS	(‐ESI,	m/z):	398.9802	[M‐H]‐,	400.9771	[M‐












Escherichia	coli	 Staphylococcus	aureus Bacillus	subtilis Aspergillus	niger	 Penicillium	sp
3a	 --	 -- -- -- --	
3b	 --	 -- -- -- --	
3c	 -	 + ++ - -	
3d	 --	 - - -- --	
3e	 --	 -- - -- --	
3f	 --	 -- -- -- --	
Cephalaxin.H2O	(12.5	mg/mL)	 --	 ++ +++ NT NT	




9.83	 (bs,	 1H,	 NH‐1).	 13C	 NMR	 (150	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
176.1	(CS‐2),	153.9	(Cq‐5"),	149.9	(Cq‐2"),	132.9	(Cq‐1"),	132.3	
(Cq‐6),	 128.1	 (CH‐4'),	 127.5	 (Cq‐3'),	 125.3	 (Cq‐5'),	 124.0	 (Cq‐
2'),	114.0	(CH‐6"),	112.7	(CH‐4"),	112.6	(CH‐3"),	104.4	(CH‐5),	
56.5	(OCH3‐2"),	55.9	(OCH3‐5"),	50.3	(CH‐4).	HRMS	(‐ESI,	m/z):	
398.9803	 [M‐H]‐,	 400.9773	 [M‐H+2]‐,	 402.9743	 [M‐H+4]‐,	
(calcd.	for	C16H13Cl2N2O2S2,	398.9801).	
6‐(2,5‐Dichlorothiophen‐3‐yl)‐4‐(4‐isopropylphenyl)‐3,4‐di	
hydropyrimidine‐2(1H)‐thione	 (3g):	 Color:	 Pale	 yellow.	 Yield:	
54%.	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	1.19	(d,	J	=	6.6	Hz,	




(150	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 174.4	 (CS‐2),	 147.9	 (CH‐4"),	
141.0	(Cq‐1"),	131.8	(Cq‐6),	127.6	(CH‐4'),	127.0	(Cq‐3'),	126.6	
(CH‐2",6"),	 126.4	 (CH‐3",5"),	 124.8	 (Cq‐5'),	 123.6	 (Cq‐2'),	
104.5	(CH‐5),	54.4	(CH‐4),	33.1	(CH(CH3)2‐4"),	23.8	(CH(CH3)2‐
4").	MS	(+ESI,	m/z	(%)):	405	([M+Na]+,	48),	407	 ([M+Na+2]+,	
37).	 409	 ([M+Na+4]+,18).	 MS	 (‐ESI,	 m/z	 (%)):	 381	 ([M‐H]‐,	
100),	383	([M‐H+2]‐,	71),	385	([M‐H+4]‐,	7).	HRMS	(‐ESI,	m/z):	
381.0059	 [M‐H]‐,	 383.0021	 [M‐H+2]‐,	 384.9999	 [M‐H+4]‐	
(calcd.	 for	 C17H15Cl2N2S2,	 381.0059).	 HRMS	 (+ESI,	 m/z):	









(125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 175.8	 (CS‐2),	 139.5	 (Cq‐1"),	
134.0	 (Cq‐8"),	 132.3	 (Cq‐6),	 129.7	 (Cq‐3"),	 129.2	 (CH‐7"),	
128.6	 (CH‐9"),	 128.1	 (CH‐4'),	 127.4	 (Cq‐3'),	 127.0	 (CH‐5"),	









8.3	 Hz,	 2H,	 H‐6",10"),	 8.68	 (s,	 1H,	 8"),	 9.09	 (bs,	 1H,	 NH‐3),	
10.01	 (bs,	 1H,	NH‐1).	 13C	NMR	 (120	MHz,	DMSO‐d6,	 δ,	 ppm):	
175.2	 (CS‐2),	 133.0	 (Cq‐1"),	 132.5	 (Cq‐6),	 131.5	 (Cq‐7",9"),	
130.2	 (Cq‐2",14"),	 129.7	 (CH‐6",	 10"),	 129.1	 (CH‐8"),	 128.2	
(CH‐4'),	 127.1	 (Cq‐3'),	 126.7	 (CH‐4",12"),	 125.5	 (CH‐5",11"),	
125.4	 (Cq‐5'),	 124.7	 (CH‐3",13"),	 124.3	 (Cq‐2'),	 105.6	 (CH‐5),	






The	 in	 vitro	 antimicrobial	 activity	 of	 pyrimidine‐2‐thione	
derivatives	 (3a‐f)	 was	 determined	 by	 the	 wells	 diffusion	
method	 [24‐26]	 (Table	 1).	 For	 these	 assays,	 cultures	 of	 the	
following	 microorganisms	 were	 used:	 two	 Gram‐positive	
(Staphylococcus	 aureus	 (ATCC	 6538)	 and	 Bacillus	 subtilis	
(ATCC	 6633)),	 one	 Gram‐negative	 (Escherichia	 coli	 (ATCC	
25922))	 bacteria,	 and	 fungal	 strains	 (Aspergillus	 niger	 and	
Penicillium	sp.	which	were	isolated	from	local	environments).		
Bacterial	 cultures	 were	 maintained	 on	 nutrient	 agar	
medium,	 while	 fungal	 cultures	 were	 maintained	 on	 potato	
dextrose	 agar	 (PDA).	 Suspensions	 of	 the	 tested	 micro‐
organisms	were	spread	on	the	solid	nutrient	agar	medium	and	
PDA	 plates.	 25±2	mg	 of	 each	 thione	 derivatives	 (3a‐f)	 were	





h	 at	 37	 °C	 for	 bacteria	 and	 25	 °C	 for	 fungi),	 positive	 anti‐
bacterial	 and	 antifungal	 activities	 were	 established	 by	 the	
presence	of	 a	measurable	 inhibition	zone	and	recorded	 in	 its	
width	 (mm)	which	 includes	 the	well	 diameter.	 Each	 test	was	
performed	in	three	replicates.	Cephalaxin.H2O	at	concentration	
12.5	 µg/mL	 was	 used	 as	 standard	 against	 bacteria	 while	








The	 one‐pot	 synthesis	 of	 4,6‐disubstituted‐3,4‐dihydro‐
pyrimidine‐2(1H)‐thiones	 (3a‐i)	was	 carried	out	by	 the	 reac‐
tion	 of	 3‐acetyl‐2,5‐dichlorothiophene	 (1)	 with	 aromatic	




The	 newly	 synthesized	 pyrimidine	 2‐thiones	 (3a‐i)	 were	
characterized	 by	 ESIMS,	 HRMS,	 1D	 and	 2D	 NMR	 techniques.	
The	 complete	 data	 are	 present	 in	 the	 experimental	 section.	
The	 1H	 NMR	 spectra	 showed	 for	 each	 compound	 two	
exchangeable	proton	signals	in	the	range	of	δ	9.48‐10.01	ppm,	
and	 δ	 8.73‐9.13	 ppm	 corresponding	 to	 NH‐1	 and	 NH‐3,	 res‐





In	 the	 13C	 NMR	 spectra	 of	 compounds	 (3a‐i),	 the	 C=S	































In	 the	present	 study,	 antimicrobial	 activity	of	new	 thione	
compounds	 (3a‐f)	 against	 one	 Gram‐negative	 bacteria	
(Escherichia	coli),	 two	Gram‐positive	bacteria	(Staphylococcus	
aureus,	Bacillus	subtilis);	and	 two	fungal	strains	 isolated	 from	
local	 environments	 (Aspergillus	 niger,	 and	 Penicillium	 sp.)	
were	 tested	 using	 diffusion	 well	 technique	 [24‐26].	 The	
antimicrobial	activity	of	all	tested	thiones	(3a‐f)	and	standards	
antimicrobial	 agents	 (Cephalaxin.H2O	 and	 Amphotericin	 B)	
were	 given	 in	 Table	 1.	 The	 results	 showed	 that	 there	 was	 a	
difference	 in	 antimicrobial	 activity	 between	 different	 thione	
compounds.	All	thiones	did	not	showed	any	activity	against	all	
tested	species,	except	 thione	derivative	(3c),	which	showed	a	
good	 activity	 against	 Gram	 positive	 bacteria	 (Staphylococcus	







have	 been	 successfully	 synthesized	 and	 characterized	 using	
different	 spectroscopic	 techniques.	 Most	 of	 the	 newly	
synthesized	 compounds	 tested	 against	 bacteria	 and	 fungi.	
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